hit counter
AngioDynamics, Inc. (ANGO) Stock News Sentiment & Price - Sentifly
ANGO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



AngioDynamics, Inc. (ANGO)

USA
Medical Instruments & Supplies
NASDAQ
ANGO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ANGO Latest news
Zacks Investment Research
Positive
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
2021-10-01 12:27

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.

Business Wire
Neutral
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance
2021-09-30 07:00

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the first quarter of fiscal year 2022, which ended August 31, 2021. “We had a solid first quarter, and our team continues to deliver strong revenue performance and invest in our growth drivers while advancing our ongoing transformation,” commented Jim Clemmer,

Business Wire
Neutral
AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021
2021-09-15 16:01

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2022 before the market open on Thursday, September 30, 2021. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, di

Zacks Investment Research
Positive
Why Is AngioDynamics (ANGO) Up 2.3% Since Last Earnings Report?
2021-08-12 13:59

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

Business Wire
Neutral
AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference
2021-07-29 16:01

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 41st Annual Canaccord Genuity Virtual Growth Conference at 9:00 a.m. ET on Wednesday, August 11, 2021. A live webcast of the pre

The Motley Fool
Neutral
After Beating Estimates, Is This Little-Known Medical Device Company a Buy?
2021-07-18 06:21

AngioDynamics exceeded analyst expectations on revenue in Q4 2021, but does that make it worth buying?

Zacks Investment Research
Positive
AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top
2021-07-14 10:51

AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.

Seeking Alpha
Neutral
AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q4 2021 Results - Earnings Call Transcript
2021-07-13 12:53

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q4 2021 Results - Earnings Call Transcript

Benzinga
Positive
AngioDynamics Breaks-Even In FY21, Issues Mixed Forecasts For FY22
2021-07-13 07:53

AngioDynamics Inc (NASDAQ: ANGO) reports break-even in 4Q of 2021 with adjusted EPS of $0.00, a turnaround from EPS of (0.06) posted a year ago. The Company witnessed the pressure from COVID-19 gradually alleviate over the year, and business is now trending close to normalized run rates.

Business Wire
Neutral
AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results
2021-07-13 07:00

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the fourth quarter and fiscal year 2021, which ended May 31, 2021. “The AngioDynamics team demonstrated excellent performance, resilience, and strong execution in what was a uniquely challenging year. We saw the pressure from COVID-19 gradually alleviate over t

Loading more news...